Antimicrobial Stewardship

Analyzing data from over 4.6 million sinusitis cases, the study emphasizes the need for focused efforts to improve adherence to treatment guidelines and ensure antibiotics are used correctly.

The World Health Organization (WHO) warns of a moderate global risk to the presence of the pathogen, hypervirulent Klebsiella pneumoniae (hvKp) sequence type (ST) 23, as it has been reported in at least 1 country in all 6 WHO Regions.

Omadacycline (Nuzyra) maintained its potency over time and did not show a decrease in effectiveness.

The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.

SHEA supports funding to address antimicrobial resistance in light of heightened challenges during the COVID-19 pandemic.

A pilot study looked at offering this form of pre-exposure prophylaxis (PrEP) to a select population to see if it could be effective in preventing sexually transmitted infections (STIs).

Paratek Pharmaceuticals has announced results from a Phase 3 study of omadacycline (Nuzyra), demonstrating its non-inferiority to moxifloxacin in treating moderate to severe community-acquired bacterial pneumonia.

Participants using nasal sprays experienced significantly shorter illness durations and reduced antibiotic usage compared to those receiving usual care.

A recent report from the CDC highlights how the COVID-19 pandemic has heightened antimicrobial resistance, resulting in a 20% increase in hospital-onset infections caused by key resistant pathogens.

Clinicians developed an algorithm and screening questionnaire for outpatient penicillin allergy evaluation, designed to stratify patients into high- and low-risk penicillin allergy groups. Here is the sample questionnaire to consider for use in clinics.

This series looks to discuss several topics around these infections including diagnosis, treatment, challenges in managing UTIs in patients with dementia and neurogenic bladders, antibiotic resistance, and considerations for patients and caregiver engagement.

A new study demonstrates that the continuous infusion of β-lactam antibiotics could offer better clinical outcomes in treating sepsis, despite the nuanced statistical results.

Meta-analysis revealing higher 90-day mortality with intermittent than continuous infusion of ß-lactams for sepsis prompts call for latter to be standard of care.

Jason Roberts, PhD, notes that the BLING study has been a great success for infectious diseases and critical care as a research program, providing strong evidence supporting a meaningful intervention for patients, specifically in clinical cure rates and the occurrence of infections with multiresistant organisms.

Jason Roberts, PhD, discusses insights from the BLING III trial, outlining its study design and primary outcomes. His analysis centers on the clinical benefits of continuous infusions while addressing the complexities of antibiotic administration in critical care. This is part 1 of a 2-part series.

Berkeley Heights, NJ-based biopharmaceutical company, CorMedix, is working towards an expanded indication for its DefenCath product, for the prevention of these healthcare-associated infections.

Understanding the evolving trends in antibiotic resistance among S aureus infections, commonly treated empirically with oral non–β-lactam antibiotics, is essential for guiding effective treatment strategies.

While the global clinical pipeline for antibacterial treatments displays notable activity, it remains inadequate to address the challenges of antimicrobial resistance.

Japan is currently facing an unprecedented surge in cases of streptococcal toxic shock syndrome (STSS), a severe and often fatal bacterial infection.

Experts emphasize prevalent waterborne illnesses and offer preventive advice for the summer season.

The latest data from the Gonococcal Antimicrobial Susceptibility Surveillance, calls for updated treatment protocols and intensified surveillance measures to address this escalating concern effectively.

BWC0977 has strong potential to effectively target the priority pathogens needed to address public health concerns.

Purportedly higher sepsis mortality in safety-net hospitals reflects less a difference in acute care than opportunities to discharge to hospice.

FDA VRBPAC recommends protection against JN1 for the fall COVID-19 vaccines, a multidrug-resistant form of gonorrhea gives cause for concern, piperacillin-tazobactam shown to have higher mortality than cefepime for sepsis, and more this week from Contagion.

A continued clarion call is being sounded about the drug-resistant pathogen.

The organization included numerous bacterium that are seen as critical threats to patients.

Piperacillin-tazobactam was associated with higher mortality than cefepime for empiric treatment of sepsis among patients without indication of anaerobic infection.

The 2024-2029 5-year UK national action plan for antimicrobial resistance is the second to emerge from the 20-year strategy announced in 2019.

While carbapenem-resistant Enterobacterales infections occur less frequently, extended-spectrum beta-lactamase-producing Enterobacterales infections are increasing.

A new series reviewing antimicrobial resistance (AMR) reduction strategies shows that available vaccines, water and sanitation, and infection control methods could greatly reduce the mortality associated with this major health crisis.